Kestra Advisory Services’s Amedisys AMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-2,488
Closed -$245K 2898
2025
Q2
$245K Buy
+2,488
New +$235K ﹤0.01% 2520
2025
Q1
Sell
-2,524
Closed -$229K 2757
2024
Q4
$229K Buy
+2,524
New +$232K ﹤0.01% 2406
2024
Q3
Sell
-2,870
Closed -$263K 2555
2024
Q2
$263K Buy
2,870
+68
+2% +$6.31K ﹤0.01% 2199
2024
Q1
$258K Buy
+2,802
New +$263K ﹤0.01% 2112
2022
Q2
Sell
-2,175
Closed -$375K 2135
2022
Q1
$375K Buy
2,175
+143
+7% +$21.4K ﹤0.01% 1462
2021
Q4
$329K Buy
2,032
+239
+13% +$38.4K ﹤0.01% 1552
2021
Q3
$267K Buy
1,793
+43
+2% +$8.94K ﹤0.01% 1769
2021
Q2
$429K Sell
1,750
-32
-2% -$8.4K ﹤0.01% 1357
2021
Q1
$472K Sell
1,782
-2,954
-62% -$833K 0.01% 1222
2020
Q4
$1.37M Buy
+4,736
New +$1.21M 0.02% 730

Other funds holding AMED

Kestra Advisory Services's AMED Position: Q3 2025 in Review

Kestra Advisory Services sold out of Amedisys (AMED) in Q3 2025, closing a stake of 2,488 shares — an estimated $245K sold.

Kestra Advisory Services first reported a position in AMED in Q4 2020 and held it in 10 quarters. The position peaked at $1.37M in Q4 2020. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Kestra Advisory Services reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Kestra Advisory Services sold 2,488 Amedisys shares in Q3 2025, an estimated $245K.
  • Kestra Advisory Services first reported a position in Amedisys in Q4 2020 and held it in 10 quarters.
  • Kestra Advisory Services's Amedisys position peaked at $1.37M in Q4 2020.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Kestra Advisory Services's 13F filing for Q3 2025, filed 14 Nov 2025.